BioNTech (NASDAQ:BNTX) Earns Buy Rating from Berenberg Bank

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating restated by analysts at Berenberg Bank in a research report issued on Friday,MarketScreener reports.

BNTX has been the subject of several other research reports. Bank of America cut their price objective on BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and raised their price objective for the company from $115.00 to $142.00 in a research report on Friday, January 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Friday, January 9th. Jefferies Financial Group reiterated a “buy” rating and issued a $151.00 price objective on shares of BioNTech in a report on Wednesday, December 3rd. Finally, Morgan Stanley reiterated an “overweight” rating and set a $134.00 price target on shares of BioNTech in a research report on Monday, November 3rd. Eleven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus price target of $140.03.

BioNTech Stock Performance

NASDAQ:BNTX opened at $118.47 on Friday. BioNTech has a twelve month low of $81.20 and a twelve month high of $126.77. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $26.68 billion, a P/E ratio of -45.05 and a beta of 1.40. The company has a fifty day moving average of $99.14 and a 200-day moving average of $103.69.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The firm had revenue of $1.78 billion for the quarter, compared to analyst estimates of $1.21 billion. During the same period last year, the company posted $0.81 earnings per share. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that BioNTech will post -3.88 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Dodge & Cox lifted its stake in BioNTech by 315.7% during the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after acquiring an additional 2,769,654 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of BioNTech by 6.7% in the second quarter. BNP Paribas Financial Markets now owns 1,275,475 shares of the company’s stock worth $135,800,000 after buying an additional 80,005 shares in the last quarter. Bank of New York Mellon Corp lifted its position in BioNTech by 58.8% during the second quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock valued at $118,045,000 after purchasing an additional 410,351 shares during the last quarter. Franklin Resources Inc. grew its holdings in BioNTech by 76.8% during the 2nd quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock valued at $80,065,000 after purchasing an additional 326,556 shares during the last quarter. Finally, Aberdeen Group plc lifted its position in shares of BioNTech by 87.2% during the second quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock worth $76,864,000 after purchasing an additional 336,260 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.